Cargando…

Clinical and Neurophysiological Follow-Up of Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with Subcutaneous Immunoglobulins: A Real-Life Single Center Study

Background: chronic idiopathic demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated neuropathy characterized by weakness, sensory symptoms and significant reduction or loss of deep tendon reflexes evolving over 2 months at least, associated with electrophysiological evidence of periph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alonge, Paolo, Di Stefano, Vincenzo, Lupica, Antonino, Gangitano, Massimo, Torrente, Angelo, Pignolo, Antonia, Maggio, Bruna, Iacono, Salvatore, Gentile, Francesca, Brighina, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856456/ https://www.ncbi.nlm.nih.gov/pubmed/36671992 http://dx.doi.org/10.3390/brainsci13010010

Ejemplares similares

Inherited Neuromuscular Disorders: Which Role for Serum Biomarkers?
por: Lupica, Antonino, et al.
Publicado: (2021)

Frequency and Correlates of Mild Cognitive Impairment in Myasthenia Gravis
por: Iacono, Salvatore, et al.
Publicado: (2023)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report
por: Cianci, Paola, et al.
Publicado: (2019)

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
por: Lupica, Antonino, et al.
Publicado: (2022)

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy
por: Markvardsen, Lars K., et al.
Publicado: (2023)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
por: Cocito, Dario, et al.
Publicado: (2023)

Sleep and Chronobiology as a Key to Understand Cluster Headache
por: Pilati, Laura, et al.
Publicado: (2023)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study
por: Iacono, Salvatore, et al.
Publicado: (2022)

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
por: Hiya, Satomi, et al.
Publicado: (2022)

OnabotulinumtoxinA Modulates Visual Cortical Excitability in Chronic Migraine: Effects of 12-Week Treatment
por: Torrente, Angelo, et al.
Publicado: (2022)

Sound-Induced Flash Illusions Support Cortex Hyperexcitability in Fibromyalgia
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis
por: Perraudin, Clémence, et al.
Publicado: (2020)

Motor Conduction Studies and Handgrip in Hereditary TTR Amyloidosis: Simple Tools to Evaluate the Upper Limbs
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
por: Alsolaihim, Alanood, et al.
Publicado: (2020)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
por: van Schaik, Ivo N., et al.
Publicado: (2016)

Advances on Cellular Clonotypic Immunity in Amyotrophic Lateral Sclerosis
por: Schirò, Giuseppe, et al.
Publicado: (2022)

Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Merkies, Ingemar S. J., et al.
Publicado: (2022)

New-onset headache following COVID-19: An Italian multicentre case series
por: Torrente, Angelo, et al.
Publicado: (2023)

Effects of a Single Session of OnabotulinumtoxinA Therapy on Sleep Quality and Psychological Measures: Preliminary Findings in a Population of Chronic Migraineurs
por: Torrente, Angelo, et al.
Publicado: (2023)

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Khoo, Anthony, et al.
Publicado: (2019)

Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins
por: Finsterer, Josef, et al.
Publicado: (2017)

Hirayama disease: Nosological classification and neuroimaging clues for diagnosis
por: Iacono, Salvatore, et al.
Publicado: (2022)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

Median-to-Ulnar Nerve Communication in Carpal Tunnel Syndrome: An Electrophysiological Study
por: Di Stefano, Vincenzo, et al.
Publicado: (2021)

Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018)

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A., et al.
Publicado: (2018)

Neurological vertigo in the emergency room in pediatric and adult age: systematic literature review and proposal for a diagnostic algorithm
por: Pellegrino, Noemi, et al.
Publicado: (2022)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Usefulness and Clinical Impact of Whole-Body MRI in Detecting Autoimmune Neuromuscular Disorders
por: Pace, Mario, et al.
Publicado: (2023)

Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up
por: Parisi, Mattia, et al.
Publicado: (2022)

A Case of Paraneoplastic Demyelinating Motor Polyneuropathy
por: Mostoufizadeh, Sohrab, et al.
Publicado: (2012)

Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A.
Publicado: (2015)

Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy
por: Allen, Jeffrey A., et al.
Publicado: (2018)

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy
por: Bril, Vera, et al.
Publicado: (2016)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ho0g0va3rjnjubo7ka7ocdm9vk